|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Analyst upgrades Covance on good results for clinical unit and fairer preclinical expectations
A stronger dollar is cushioning the U.S. markets from the volatility in overseas markets, Cramer says.
Contract research organizations aren't without risks of course, but they do offer some protection against the vagaries of the industry.
The investment services company deserves to go higher, Cramer says.
Cramer says the company can capitalize on the older video-game player.
Cramer says the brokerage firm is the only one that handled the mortgage mess right.
Cramer likes the drugstore chain despite what he considers an ill-advised downgrade.
You can find quality in firms that do outsourced drug trials, but pick your spots and know the risks.
The contract is the largest in the drug research company's history.
Allegations of questionable practices have battered drug-testing firm SFBC, but it's on track for growth.
SFBC has been targeted by the media and Congress. But it's still a reasonable speculative buy.
The stocks recommended in this column have handily beat the S&P 500.
Expect a few days of swings around this level, and then as we approach month-end, a drop.
Shares of the drug-development services company get a clean bill of health.
There's a lot to like about this provider of research services.
The indices could test their 200-day exponential moving average before this correction ends.
The Arms Index shows an even more overbought condition than last week.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.